Trial Information: 50 patients are being recruited for a Phase I trial of the new anti-CD40 monoclonal antibody lucatumumab (aka HCD122). Patients must have follicular lymphoma and have become resistant to rituximab following previous therapy. Patients will be given combination therapy of lucatumumab with bendamustine, a relatively new alkylating agent.
Showing posts with label Lucatumumab. Show all posts
Showing posts with label Lucatumumab. Show all posts
Thursday, January 13, 2011
Wednesday, January 12, 2011
New Drug Information: Lucatumumab Anti-CD40 Monoclonal Antibody
Also known as: HCD122
Drug Information: Lucatumumab is one of several experimental anti-CD40 monoclonal antibodies. CD40 is a cellular surface protein involved in immune system signaling, which is present on cancerous B cells. The drug's developer, Novartis, believes that it both blocks proliferation of malignant cells and attracts other immune system cells to attack the cancer. It is given intravenously on a weekly basis for multi-week treatment cycles.
Drug Information: Lucatumumab is one of several experimental anti-CD40 monoclonal antibodies. CD40 is a cellular surface protein involved in immune system signaling, which is present on cancerous B cells. The drug's developer, Novartis, believes that it both blocks proliferation of malignant cells and attracts other immune system cells to attack the cancer. It is given intravenously on a weekly basis for multi-week treatment cycles.
Subscribe to:
Posts (Atom)